Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Wolfgang Miesbach: A Snake Venom-Derived Factor X Activator for Haemophilia with Inhibitors
Wolfgang Miesbach/LinkedIn
Mar 25, 2026, 14:51

Wolfgang Miesbach: A Snake Venom-Derived Factor X Activator for Haemophilia with Inhibitors

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn about a recent article by Wei Liu et al, published in Blood Advances:

”A snake venom-derived Factor X activator for haemophilia with inhibitors.

Published in Blood Advances, this multicentre phase II trial from China (9 centres, Chinese Academy of Sciences) evaluates bemiltenase alfa, purified from Daboia russelii siamensis (Russell’s viper) venom, as an on-demand haemostatic treatment for patients with haemophilia A or B and inhibitors (HAwI/HBwI).

Inhibitors complicate care in up to 30% of severe HA and 5% of severe HB patients.

Existing bypassing agents show variable efficacy — and crucially, no current non-factor therapy (emicizumab, fitusiran, concizumab) can treat active bleeding.

The mechanism of bemiltenase alfa: It directly activates Factor X — independently of FVIII or FIX — triggering a rapid thrombin burst via the common coagulation pathway.

Results of the clinical study

  • Phase IIa: 94.1% effective haemostasis across 135 bleeding episodes
  • Phase IIb: 81.9% effective haemostasis across 144 bleeding episodes
  • Median time to resolution: 5.5 h from first dose
  • Approximately 77% of bleeds controlled with 1–2 doses only
  • Rescue therapy required in just 1.4% of episodes
  • No serious adverse events, no DIC, no drug-related thromboembolism

How to use it

  • IV injection, 0.10 U/kg every 4 hours (up to 6 doses per bleed)
  • Half-life ~8 h; onset of APTT reduction and thrombin generation improvement within 10 minutes
  • Higher dose (0.16 U/kg) available as escalation for non-responders
  • An 8-hour dosing interval is under investigation

FDA Orphan Drug Designation granted June 2024. Phase III trial (NCT06922045) ongoing.”

Title: A specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase I/II trials

Authors: Wei Liu, Hu Zhou, Ruibin Huang, Xin Du, Panjing Wang, Zeping Zhou, Changcheng Zheng, Shifeng Lou, Jun Ma, Yanping Song, Xinyue Dai, Xiaomin Wang, Renchi Yang, Lei Zhang

Read the Full Article on Blood Advances

Wolfgang Miesbach: A Snake Venom-Derived Factor X Activator for Haemophilia with Inhibitors

Stay updated on all scientific advances with Hemostasis Today.

ASH bemiltenase alfa bleeding disorders Blood Advances Changcheng Zheng Chinese Academy of Sciences Factor X FDA Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Hu Zhou Jun Ma Lei Zhang Medicine Panjing Wang Renchi Yang Ruibin Huang Russell's viper Shifeng Lou Snake venom Wei Liu Wolfgang Miesbach Xiaomin Wang Xin Du Xinyue Dai Yanping Song Zeping Zhou
NewsFeed